Matsayin faɗakarwar zangon kore ne: Don sabon matsayin faɗakarwar harabar UMMS, labarai da albarkatu, da fatan za a ziyarci umassmed.edu/coronavirus
A matsayin wani ɓangare na Cibiyar Kiwon Lafiya ta Kasa ta Tsarin Gaggawar Gaggawar Gaggawa (RADx), wani dogon binciken da masu bincike daga Jami'ar Massachusetts Medical School suka rubuta ya bayyana cewa gwajin PCR da saurin antigen na SARS-CoV-2 suna da amfani wajen ganowa. cututtuka Yana da tasiri daidai.Ba da aƙalla sau biyu a mako.
A cewar sanarwar manema labarai na NIH, kodayake ana ɗaukar gwajin PCR na sirri a matsayin ma'aunin zinare, yana da hankali fiye da gwajin antigen, musamman a farkon matakan kamuwa da cuta, amma sakamakon ya nuna cewa lokacin da ake yin shi akai-akai a matsayin wani ɓangare na shirin tantancewa, biyun. hanyoyin gwaji sun fi hankali.Hankali na iya kaiwa 98%.Wannan labari ne mai kyau ga shirye-shiryen rigakafi mai yawa, saboda gwajin antigen a wurin kulawa ko a gida na iya samar da sakamako nan da nan ba tare da takardar sayan magani ba kuma ba shi da tsada fiye da gwajin gwaji.
An buga binciken ne a cikin "Journal of Infectious Diseases" a ranar 30 ga Yuni. Masu bincike daga Jami'ar Illinois a Urbana-Champaign, Johns Hopkins School of Medicine, da Cibiyar Nazarin Halittar Halittu da Bioengineering da suka rubuta wannan takarda sune: Mataimakin Farfesa. na Magunguna Laura L. · Gibson (Laura L. Gibson);Alyssa N. Owens, Ph.D., Mai Gudanar da Bincike;John P. Broach, MD, MBA, MBA, Mataimakin Farfesa na Magungunan Gaggawa;Bruce A. Barton, PhD, Yawan jama'a da Farfesa na Kimiyyar Kiwon Lafiyar Kiwon Lafiya;Peter Lazar, mai haɓaka bayanan aikace-aikacen;da David D. McManus, MD, Richard M. Haidack Farfesa na Magunguna, Shugaban Magunguna da Farfesa.
Dr. Bruce Tromberg, Daraktan NIBIB, wani reshen NIH, ya ce: “Yin saurin gwajin antigen a gida sau biyu zuwa uku a mako hanya ce mai ƙarfi da dacewa ga mutane don yin gwajin cutar COVID-19.“Tare da sake buɗe makarantu da kasuwanci, haɗarin kamuwa da cuta na iya canzawa kowace rana.Ci gaba da gwajin antigen na iya taimakawa mutane sarrafa wannan haɗarin kuma suyi sauri don hana yaduwar cutar. ”
Masu bincike sun tattara nau'i biyu na swabs na hanci da samfuran salwa don ma'aikata da ɗalibai masu halartar yayin shirin gwajin COVID-19 a Jami'ar Illinois a Urbana-Champaign na kwanaki 14 a jere.An aika ɗaya daga cikin swabs na kowane ɗan takara zuwa dakin gwaje-gwaje na Jami'ar Johns Hopkins don lura da haɓakar ƙwayoyin cuta a cikin al'ada da kuma auna lokacin da batun zai iya yada cutar ga wasu.
Masu binciken sun kwatanta hanyoyin gano COVID-19 guda uku: gwajin PCR na salva, gwajin PCR na hanci, da samfurin hanci da sauri gwajin antigen.Sun ƙididdige hankalin kowace hanyar gwaji don gano SARS-CoV-2 kuma sun auna kasancewar kwayar cutar a cikin makonni biyu na kamuwa da cuta.
Lokacin da masu binciken suka ƙididdige ƙimar gwajin dangane da ƙimar gwajin kowane kwana uku, sun ba da rahoton cewa ko sun yi amfani da gwajin saurin antigen ko gwajin PCR, ƙwarewar gano kamuwa da cuta ya fi 98%.Lokacin da kawai suka tantance yawan ganowa sau ɗaya a mako, ƙwarewar gano PCR ga hanci da ɗigo har yanzu yana da girma, kusan 98%, amma ƙwarewar gano antigen ya ragu zuwa 80%.
"Kalubalen fassarar PCR ko sakamakon gwajin antigen shine gwajin inganci bazai nuna kasancewar kamuwa da cuta ba (ƙananan ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun bayanai) ko kuma ba za su iya gano ƙwayar cuta mai rai a cikin samfurin (ƙananan hankali ba), bi da bi," in ji shugaban haɗin gwiwar Dr. Gibson.RADx Tech tushen bincike na asibiti.
“Bambancin wannan binciken shine mun haɗa PCR da gano antigen tare da al'adar ƙwayar cuta azaman alamar cuta.Wannan ƙirar bincike ta bayyana hanya mafi kyau don amfani da kowane nau'in gwaji, kuma yana rage haɗarin COVID-19 da ake zargi da haƙuri ya bayyana tasirin ƙalubalen sakamakon su."
Dokta Nathaniel Hafer, mataimakin farfesa a likitancin kwayoyin halitta kuma babban mai bincike na RADx Tech Study Logistics Core, ya ce: "A matsayin misali na tasirin aikinmu, bayanan da muke tattarawa suna taimakawa wajen samar da CDC bayanai game da yawan jama'a."
Dokta Hafer ya nuna muhimmiyar rawa na Makarantar Magunguna ta UMass a cikin ƙira, aiwatarwa da kuma nazarin wannan gwaji na hankali.Ya yaba wa tawagar masu bincike na Makarantar Kiwon Lafiya ta Jami'ar Massachusetts karkashin jagorancin Dr. Broach, ciki har da darektan ayyuka Gul Nowshad da navigator Bernadette Shaw-saboda rawar da suka taka wajen lura da masu halartar binciken a cikin ɗakin kwanan dalibai muhimmiyar rawa a Jami'ar. na Illinois.
Wani rahoto mai alaka daga UMassMed News: Yayin ziyarar Majalisa zuwa harabar NIH, an jaddada shirin RADx.Makarantar Kiwon Lafiya ta UMass tana taimakawa NIH RADx don haɓaka sabuwar fasahar gwajin COVID.Labari kanun labarai: Makarantar Kiwon Lafiya ta UMass ta karɓi kyautar NIH $ 100 miliyan don haɓaka gwajin COVID-19 mai sauri, mai sauƙi
Questions or comments? Email: UMMSCommunications@umassmed.edu Tel: 508-856-2000 • 508-856-3797 (fax)
Lokacin aikawa: Yuli-14-2021